Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors
Year: 2004
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: F. Robert, C. Garrett, W. R. Dinwoodie, D. M. Sullivan, M. Bishop, M. Amantea, M. Zhang, S. D. Reich
Institutions: Moffitt Cancer Center, University of Alabama at Birmingham
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2205995839